

1

2 **High neutralizing activity against Omicron BA.2 can be induced by COVID-19 mRNA**

3 **booster vaccination**

4

5 Lidya Handayani Tjan, MD, PhD; Koichi Furukawa, MD; Yukiya Kurahashi, MD;

6 Silvia Sutandhio, MD; Mitsuhiro Nishimura, PhD; Jun Arie, DVM, PhD; Yasuko Mori, MD,

7 PhD

8

9 Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate

10 School of Medicine, Kobe, Hyogo 650-0017, Japan

11

12 **Corresponding author:**

13 Prof. Yasuko Mori

14 Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate

15 School of Medicine.

16 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo Japan, 650-0017

17 Tel: +81-78-382-6272; Fax: +81-78-382-6879

18 E-mail: ymori@med.kobe-u.ac.jp

19

20 Abstract

21 The VOC of SARS-CoV-2, Omicron (BA.1, BA.1.1, BA.2, or BA.3), is associated with an
22 increased risk of reinfection. BA.2 has become the next dominant variant worldwide.

23 Although BA.2 infection has been shown to be mild illness, its high transmissibility will
24 result in high numbers of cases. In response to the surge of Omicron BA.1 cases, booster
25 vaccination was initiated in many countries. But there is limited evidence regarding the
26 effectiveness of a booster vaccination against BA.2. We collected blood samples from 84
27 physicians at Kobe University Hospital, Japan, in January 2022 ~7 months after they had
28 received two BNT162b2 vaccinations and ~2 weeks after their booster vaccination. We
29 performed a serum neutralizing assay against BA.2 using authentic virus.

30 Although most of the participants had no or a very low titer of neutralizing antibody against
31 BA.2 at 7 months after two BNT162b2 vaccinations, the titer increased significantly at 2
32 weeks after the booster vaccination.

33

34

35

36 **Introduction**

37 The most recently designated VOC of SARS-CoV-2, Omicron, is associated with an
38 increased risk of reinfection¹. Among four sub-lineages of Omicron (BA.1, BA.1.1, BA.2,
39 and BA.3), BA.1 has spread to >151 countries and is responsible for the greatly increased
40 number of COVID-19 cases worldwide. However, Omicron BA.2 has also been detected in
41 ≥85 countries and became the dominant lineage in 18 countries by mid-February 2022². BA.2
42 has become the next dominant variant worldwide.

43 A recent epidemiological study in South Africa suggested that the clinical profile of illness
44 caused by BA.1 infection is similar to that caused by BA.2³. Although BA.2 infection has
45 been shown to be mild illness, its high transmissibility will result in high numbers of cases
46 with considerable societal impacts, e.g., greater work absences, including healthcare and
47 public employees.

48 In response to the surge of Omicron BA.1 cases, booster vaccination was initiated in many
49 countries. We and others have previously reported that BA.1 escapes two doses of
50 BNT162b2 mRNA vaccine-induced neutralization and that a booster (3rd) vaccination is
51 required to induce the neutralizing antibody against BA.1^{4,5}. But there is limited evidence
52 regarding the effectiveness of a booster vaccination against BA.2⁶.

53

54 **Methods**

55 We collected blood samples from 84 physicians at Kobe University Hospital, Japan, in
56 January 2022 (median age 44 years, IQR 33–58) ~7 months after they had received two
57 BNT162b2 vaccinations and ~2 weeks after their booster vaccination. We performed a serum
58 neutralizing assay against BA.2 using authentic virus as described⁴. No participants had a
59 history of SARS-CoV-2 infection. The study was approved by the ethical committee of the

60 Kobe University Graduate School of Medicine (approval code: B200200). All participants
61 were recruited with their written consent.

62

63 **Results**

64 The results demonstrated that similar to BA.1⁴, most of the participants had no or a very low
65 titer of neutralizing antibody against BA.2 at 7 months after two BNT162b2 vaccinations
66 (GMT 1·18, 95%CI: 1·09–1·27). However, the titer increased significantly at 2 weeks after
67 the booster vaccination (GMT 36·44, 95%CI: 30·53–43·50), $p < 0·001$ (Fig. 1).

68

69 **Discussion**

70 These results indicate that the booster vaccination could induce neutralizing immunity against
71 Omicron BA.2 (as it has against BA.1), and that a booster dose of BNT162b2 mRNA vaccine
72 induces a high cross-neutralizing response against SARS-CoV-2 variants⁴, indicating the
73 booster vaccination is meaningful and hopeful for the suppression of BA.2 pandemic and can
74 activate memory B cells that could produce neutralizing antibodies recognizing epitopes
75 conserved among SARS-CoV-2 variants.

76

77 **Conflict of interest**

78 All authors declare no conflicts of interest with respect to this letter. Authors have submitted
79 the ICMJE Form for Disclosure of Conflicts of Interest.

80

81 **Acknowledgments**

82 We gratefully acknowledge Kazuro Sugimura MD, PhD (Superintendent, Hyogo Prefectural
83 Hospital Agency and Professor, Kobe University) for giving his full support to this study. We

84 also thank the National Institute of Infectious Disease Japan for providing the SARS-CoV-2

85 Omicron variants BA.2.

86

87 **Figure Legend**

88 **Figure. 1.** Neutralizing antibody titers against Omicron BA.2 in BNT162b2 mRNA-
89 vaccinated adult males (n=84) at 7 months after they had received two vaccine doses and at 2
90 weeks after a booster vaccination. The limit of detection is displayed with a dotted horizontal
91 line and the horizontal line shows the geometric mean titer. The titers were compared by the
92 two-sample Wilcoxon rank-sum (Mann-Whitney) test; two-tailed p-values were calculated.

93

94 **References**

- 95 1. Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the Omicron
96 Variant from Previous SARS-CoV-2 Infection. *N Engl J Med.* Feb 9
97 2022;doi:10.1056/NEJMc2200133
- 98 2. World Health Organization (WHO). COVID-19 Weekly Epidemiological Update Edition
99 80. Updated 22 February 2022. Accessed Mar 15, 2022.
100 [https://apps.who.int/iris/bitstream/handle/10665/352199/CoV-weekly-sitrep22Feb22-](https://apps.who.int/iris/bitstream/handle/10665/352199/CoV-weekly-sitrep22Feb22-eng.pdf)
101 [eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/352199/CoV-weekly-sitrep22Feb22-eng.pdf)
- 102 3. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the
103 SARS-CoV-2 omicron variant in South Africa: a data linkage study. *Lancet.* Jan 29
104 2022;399(10323):437-446. doi:10.1016/S0140-6736(22)00017-4
- 105 4. Furukawa K, Tjan LH, Kurahashi Y, et al. Acquired neutralizing breadth against SARS-
106 CoV-2 variants including Omicron after three doses of mRNA COVID-19 vaccination and the
107 vaccine efficacy. *medRxiv* [preprint].
108 2022;doi:10.1101/2022.01.25.22269735doi:<https://doi.org/10.1101/2022.01.25.22269735>
- 109 5. Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 Vaccination Neutralization of SARS-
110 CoV-2 Omicron Infection. *N Engl J Med.* Feb 3 2022;386(5):492-494.
111 doi:10.1056/NEJMc2119358
- 112 6. Chen LL, Chu AW, Zhang RR, Hung IF, To KK. Serum neutralisation of the SARS-CoV-2
113 omicron sublineage BA.2. *The Lancet Microbe.* Mar 28 2022;doi:10.1016/S2666-
114 5247(22)00060-X
- 115

